ArticleMedicine and pharmacy reports2025
Early cognitive and quality of life changes after transfemoral transcatheter aortic valve replacement.
Article in Medicine and pharmacy reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Cognitive impairment has been associated with the presence of severe aortic stenosis (AS). Our study evaluated the early changes in cognitive function and quality of life in patients with severe AS who underwent transfemoral transcatheter aortic valve replacement (TAVR). Methods: The cognitive function and quality of life of patients with severe symptomatic AS who underwent transfemoral TAVR were assessed with the Montreal Cognitive Assessment (MoCA) and the EQ-5D-3L questionnaire, respectively. The tests were performed at the time of admission and at 48 to 72 h after TAVR. Results: The study group included 37 patients with a mean age of 78 years. Cognitive improvement was observed in 72.9% of patients. A higher MoCA score at baseline was correlated with a better functional outcome after TAVR (r=0.49, p=0.02). Patients with an early post-procedural increase in MoCA scores had a smaller aortic valve area at baseline as compared to patients without cognitive improvement (0.5±0.2 vs. 0.7±0.1 sq.cm, p=0.02). The baseline aortic valve area was associated with an increase in MoCA scores at an optimal cutoff value ≤0.65 sq.cm (AUC 0.739; p=0.005). A significant increase in median EQ-5D-3L scores was observed between baseline and follow-up (60 (51-70) vs. 73 (65-80) points, p<0.001). The lack of improvement in functional status was associated with a prolonged stay in the Intensive Care Unit (ICU) (r=-0.46, p=0.02). Conclusions: In patients with severe symptomatic AS, a smaller aortic valve area at baseline was associated with an early cognitive improvement after transfemoral TAVR. Baseline cognition and the length of stay in the ICU influenced the early functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.